NAD(P)H-Glo™ Detection System
Monitor the Concentration of Reduced Forms of NADH and NADPH
- Highly sensitive and rapid bioluminescent assay
- Easily adapted for high-throughput format
- Simple add-mix-measure protocol
Catalog Number:
Size
Catalog Number: G9061
Catalog Number: G9062
The NAD(P)H-Glo™ Detection System is a bioluminescent, homogeneous, single-reagent-addition assay that quantitatively monitors the concentration of the reduced forms of NADH and NADPH levels in enzymatic reactions. The oxidized forms, NAD+ and NADP+, are not detected and do not interfere with quantitation.
The assay is rapid, requiring only a 40- to 60-minute incubation, has a broad linear range (25nM-50µM) and high signal-to background ratio (~400). Low nanomolar sensitivity, 25nM, allows direct in-well detection. The assay is well suited to measuring NAD(P)H production or consumption in high-throughput formats.
Assay Chemistry
In the presence of NAD(P)H, a reductase reduces the proluciferin reductase substrate to form luciferin. Luciferin is quantified using Ultra-Glo™ Recombinant Luciferase, which is a component of the Luciferin Detection Reagent, and the light signal produced is proportional to the amount of NAD(P)H in the sample.
Sensitive and Selective
The assay is selective for the reduced forms of NADH and NADPH levels in enzymatic reactions.
Compatible with High-Throughput Systems
The simple add-and-read protocols are compatible with automated and high-throughput workflow, and the flexible chemistries adapt to 96-, 384- and 1,536-well plate formats and high-throughput systems. They yield Z′ values >0.7.
Assays were performed using 8µl of the indicated concentration of NADH with 8µl of the appropriate Luciferin Detection Reagent in 384-well plates. S/B = signal-to-background ratio.
The NAD(P)H-Glo™ Assay detects only NADH and NADPH.
Case Study
Researchers at BioAscent have implemented the NAD(P)H-Glo™ Assay for HTS. In this project, Dr McElroy and his team used the NAD(P)H-Glo™ Assay to screen 50,000 compounds against a poorly characterized enzyme that is a potential drug target. NAD(P)H-Glo was chosen as it has high sensitivity, with a wide dynamic range and high signal-to-background ratios.
Protocols
Complete Protocol
Specifications
Catalog Number:
選択製品の構成品内容
| Item | Part # | Size | Concentration |
|---|---|---|---|
Reductase |
G884A | 1 × 55μl | 6mg/ml |
Reductase Substrate |
G885A | 1 × 55μl | |
|
Luciferin Detection Reagent |
V859A | 1 × 1 each | |
|
Reconstitution Buffer |
V865A | 1 × 10ml |
U.S. Pat. Nos. 9,273,343 and 9,951,372, European Pat. No. 2751089, Japanese Pat. No. 6067019 and other patents pending.
選択製品の構成品内容
| Item | Part # | Size | Concentration |
|---|---|---|---|
Reductase |
G884B | 1 × 275μl | 6mg/ml |
Reductase Substrate |
G885B | 1 × 275μl | |
|
Luciferin Detection Reagent |
V859B | 1 × 1 each | |
|
Reconstitution Buffer |
V865B | 1 × 50ml |
U.S. Pat. Nos. 9,273,343 and 9,951,372, European Pat. No. 2751089, Japanese Pat. No. 6067019 and other patents pending.
Resources
サイテーション
-
Secreted APE1/Ref-1 inhibits TNF-α-stimulated endothelial inflammation via thiol-disulfide exchange in TNF receptor.
2016
Sci. Rep.
-- -
Large-scale label-free comparative proteomics analysis of polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAFV600E mutant melanoma cells.
2014
J. Proteome Res.
-- -
Crystal structure of the emerging cancer target MTHFD2 in complex with a substrate-based inhibitor.
2017
Cancer Res.
-- -
Compensation for intracellular environment in expression levels of mammalian circadian clock genes.
2014
Sci. Rep.
-- - See all citations
Related Products
類似製品
Nicotinamide Adenine Dinucleotide Cell-Based Assays
細胞内のニコチンアミドアデニンジヌクレオチド（ NAD(P)+ あるいは NAD(P)H ）の全体量あるいはその比率を検出する高感度な発光アッセイ
G9071, G9072, G9081, G9082
Glucose Uptake-Glo™ Assay
2DG6P の検出をベースにした哺乳動物細胞でのNon-RI グルコース取込み量を測定する発光アッセイ
J1341, J1342, J1343
Lactate-Glo™ Assay
様々なサンプル種より迅速に乳酸を検出する発光アッセイ
J5021, J5022
GSH/GSSG-Glo™ Assay
培養細胞中の総グルタチオン(GSH +GSSG)、GSSG または GSH/GSSG 比を測定するための発光アッセイ
V6611, V6612
